## First-Line Anti-VEGF Therapy in Diabetic Macular Edema ### Current Evidence & Guidelines **Key Point:** Aflibercept (Eylea) is now considered the preferred first-line intravitreal agent for DME, particularly in treatment-naïve patients, based on the VIVID/VISTA trials and subsequent real-world evidence. **High-Yield:** The DRCR.net Protocol T (2015) demonstrated that ranibizumab, bevacizumab, and aflibercept all improve vision in DME, but aflibercept showed superior anatomical outcomes (greater reduction in central retinal thickness) and faster resolution of edema. ### Why Aflibercept is Preferred | Feature | Aflibercept | Ranibizumab | Bevacizumab | | --- | --- | --- | --- | | **Mechanism** | VEGF-A, VEGF-B, PlGF inhibitor | VEGF-A inhibitor (monoclonal antibody) | VEGF-A inhibitor (monoclonal antibody) | | **Binding affinity** | Highest (2:1 VEGF:drug ratio) | Lower | Lower | | **Dosing frequency** | 8 weeks (after 4 weekly loading) | 4 weeks | 4 weeks | | **Anatomical efficacy** | Superior CRT reduction | Good | Good | | **Onset of action** | Faster | Slower | Slower | | **Cost** | Higher | Moderate | Lower (off-label) | **Clinical Pearl:** Aflibercept's broader inhibition profile (includes PlGF) and higher binding affinity translate to faster and more durable edema resolution, reducing treatment burden with less frequent injections. ### Treatment Algorithm for DME ```mermaid flowchart TD A[DME confirmed on OCT]:::outcome --> B{Center-involving?}:::decision B -->|Yes| C[Anti-VEGF indicated]:::action B -->|No| D[Observe or laser if thick]:::action C --> E{Treatment-naïve?}:::decision E -->|Yes| F[Aflibercept preferred]:::action E -->|No| G[Continue prior agent or switch]:::action F --> H[4 weekly, then 8-weekly dosing]:::action H --> I[Reassess at 4 weeks]:::outcome ``` **High-Yield:** Ranibizumab and bevacizumab remain acceptable alternatives if aflibercept is contraindicated or unavailable, but aflibercept is now the guideline-preferred first choice. [cite:American Academy of Ophthalmology Preferred Practice Pattern: Diabetic Retinopathy 2023]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.